Skip to content

Gait analysis after THA

GAIT ANALYSIS AFTER TOTAL HIP ARTHROPLASTY Reliability of gait analysis tests for both the anterior and posterolateral approach. A pilot study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25459
Enrollment
12
Registered
2017-04-13
Start date
2017-06-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Patients in the anterior approach group will undergo THA using the minimally invasive single-incision anterior approach. An anterior incision centred over the hip joint is made in a supine patient. Af

Sponsors

Martini Hospital Groningen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Age between 18 – 90 years; - Indication for THA is primary or secondary symptomatic osteoarthritis

Exclusion criteria

Exclusion criteria: - A history of previous surgery on the ipsilateral hip; - symptomatic osteoarthritis of the contralateral hip; - a hip prosthesis at the contralateral side two years prior to current trial; - symptomatic osteoarthritis of the knee; - peripheral neuropathy; - (active) arthritis (e.g. rheumatic disease); - a history of CVA; - COPD GOLD III or IV - NYHA class III or IV - cognitive impairments.

Design outcomes

Primary

MeasureTime frame
The primary objective is to conduct a prospective pilot study to assess the optimal measurements of gait function following THA via both the anterior and the posterolateral approach. This will be measured with three different methods: -Ground reaction forces will be measured during the stance phase of gait with force plates; -Three dimensional (3D) motion analysis will assess the movement of the patients’ body; -muscle activity during gait will be measured with EMG.

Contacts

Public ContactK. (Kyrill) Rykov

Department of Orthopaedics - Martini Hospital

Email: k.rykov@mzh.nlPhone: 050 524 59 70

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)